{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:15Z","timestamp":1791060915968,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.104117","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:19:36Z","timestamp":1785424776000},"page":"104117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Patient-Reported Outcomes from NRG Oncology\/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-9776","authenticated-orcid":false,"given":"Benjamin","family":"Movsas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofeek K.","family":"Owonikoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuaki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie G.","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Brownstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Kuzma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedayo","family":"Onitilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mulford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Watkins","family":"Bruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104117_bib1","first-page":"889","article-title":"Atezolizumab plus chemotherapy in small-cell lung cancer","volume":"380","author":"Horn","year":"2019","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104117_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2026.104117_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib5","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104117_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104117_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-5002(95)00450-F","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument","volume":"12","author":"Cella","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104117_bib10","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1200\/jco.2008.26.15_suppl.6537","article-title":"The Patient Reported Outcomes Measurement Information System-Cancer (PROMIS-Ca): cancer-specific application of a generic fatigue measure","volume":"26","author":"Cella","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jtho.2026.104117_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.hoc.2005.02.009","article-title":"Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale","volume":"19","author":"Butt","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtho.2026.104117_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0895-4356(01)00477-2","article-title":"What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592","volume":"55","author":"Cella","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtho.2026.104117_bib14","series-title":"Presented at the International Conference on Survey Methods in Multinational, Multiregional, and Multicultural Contexts (3MC)","article-title":"Developing a fatigue item bank from the patient-reported outcomes measurement information system (PROMIS FIB version 1)","author":"Lai","year":"2008"},{"key":"10.1016\/j.jtho.2026.104117_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cllc.2023.02.001","article-title":"Thoracic radiation in limited stage small cell lung cancer: trends in radiation fractionation","volume":"24","author":"Kazemi","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104117_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35663","article-title":"Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance","volume":"131","author":"Ganti","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.104117_bib19","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.ijrobp.2024.01.218","article-title":"Are we finally ready to implement twice-daily thoracic radiation therapy in limited-stage small cell lung cancer?","volume":"119","author":"Gr\u00f8nberg","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2026.104117_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104117_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2022.02.002","article-title":"Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer","volume":"166","author":"Killingberg","year":"2022","journal-title":"Lung Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:23:51Z","timestamp":1791059031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426005708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"alternative-id":["S1556086426005708"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104117","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Patient-Reported Outcomes from NRG Oncology\/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104117"}}